Parameswaran Hari, MD, MRCP

Chief, Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

Hindi, Urdu, Tamil, Malayalam, English

Contact Information

Education

MD - Doctor of Medicine
MRCP (U.K.) - Member Royal College of Physicians

Biography

Parameswaran Hari, MD, MRCP, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief in the Division of Hematology and Oncology in the Department of Medicine. After medical school in India, he completed training in Internal Medicine and Hematology in the United Kingdom and then in Medical Oncology and Transplantation at the Medical College of Wisconsin.

Research Interests

His primary clinical interests are in cellular therapies and plasma cell disorders - multiple Myeloma, Amyloidosis and other monoclonal gammopathies. Dr. Hari is also Scientific Director of the plasma cell disorders working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

Autonomic nervous system control of multiple myeloma.

(Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S.) Blood Rev. 2021 Mar;46:100741 PMID: 32807576 PMCID: PMC7876165 SCOPUS ID: 2-s2.0-85089534779 08/19/2020
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

(Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG.) The Lancet Oncology. March 2021;22(3):e105-e118 SCOPUS ID: 2-s2.0-85101689680 03/01/2021
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden

(Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A.) Transplantation and Cellular Therapy. 2021 SCOPUS ID: 2-s2.0-85101183550 01/01/2021
Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005))

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplantation and Cellular Therapy. 2021 SCOPUS ID: 2-s2.0-85101258094 01/01/2021
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

(Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L.) Am J Hematol. 2021 01;96(1):E5-E8 PMID: 32974944 SCOPUS ID: 2-s2.0-85092920395 09/26/2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.

(Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A.) Cancer. 2020 Dec 01;126(23):5077-5087 PMID: 32965680 SCOPUS ID: 2-s2.0-85091306660 09/24/2020
Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.

(Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S.) Biol Blood Marrow Transplant. 2020 12;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.

(Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ.) Leuk Lymphoma. 2020 12;61(14):3484-3492 PMID: 32865474 PMCID: PMC7786301 SCOPUS ID: 2-s2.0-85089967898 09/01/2020
In response to American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

(Reddy P, Davies S, Majhail N, Sandmaier B, Hari P, Cutler C.) Blood Adv. 2020 11 10;4(21):5431-5432 PMID: 33152057 PMCID: PMC7656930 SCOPUS ID: 2-s2.0-85096913166 11/06/2020
Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.

(Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P.) Br J Haematol. 2020 11;191(3):442-452 PMID: 33094839 PMCID: PMC7990054 SCOPUS ID: 2-s2.0-85088463591 10/24/2020
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.

(Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A.) Cancer. 2020 Jan 01;127(1):82-92 PMID: 32966625 PMCID: PMC7736245 SCOPUS ID: 2-s2.0-85091313309 09/24/2020